GIPR-agonist compounds
US11254721B2 · kind B2 · utility
2Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2020 |
| Grant date | Feb 22, 2022 |
| Priority date | — |
| Expiry date | Jul 29, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds having activity at the human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to compounds having an extended duration of action at the GIP receptor. Such compounds may be useful in the treatment of diabetes, including type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.